# Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Source: https://onco.cc/trials/nct05117242/  
OnCo record `nct05117242` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acasunlimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, active and no longer recruiting.

## Summary

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer is a phase 2 interventional study registered as NCT05117242 by Genmab, with 125 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2024-12-02. Interventions recorded: Acasunlimab, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer Metastatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05117242
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
- Sponsor: Genmab
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT05117242: https://clinicaltrials.gov/study/NCT05117242

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Acasunlimab](https://onco.cc/drugs/acasunlimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct05117242.json